Practical Management of Metastatic Prostate Cancer: Guidelines and Beyond - Los Angeles (2017)

October 29, 2017

Urologists continue to indicate one of the greatest educational needs in treating CRPC patients is the sequencing of agents. With the numerous new treatments now available to urologists to manage the CRPC patient, sequencing and managing the side effects of each treatment have become increasingly important. In addition, studies are demonstrating that earlier treatment with these systemic agents has improved efficacy. Urologists play a central role in the management of metastatic and castrate resistant prostate cancer and as their role continues to increase, knowledge of the various side effects of the numerous treatments that are available is paramount.

This course will provide essential information on the role of systemic therapy in the treatment of metastatic prostate cancer, focusing upon a thorough review of the AUA CRPC Guidelines, followed by management of castrate sensitive prostate cancer with systemic agents, sequencing of agents, managing side effects of treatments, management of comorbid conditions, and identifying potential interactions between agents. Additionally, the course will include a section on pain management and training on counseling/support of patients in end-of-life issues.

Target Audience

  • APN/PA
  • Non-Urologist MD
  • Nurse
  • Urologist

Learning Objectives

At the end of the course, attendees will be able to:

  1. Apply the AUA CRPC Guidelines for FDA approved agents in the management of CRPC and optimization of the AUA algorithm for patient clinical benefit.
  2. Evaluate and diagnose CRPC patients and discuss the sequencing and combinatorial treatment strategies from both clinical and administrative perspectives.
  3. Analyze the role of systemic agents in androgen sensitive metastatic prostate cancer.
  4. Examine the side effect profiles and potential interactions of various therapeutic strategies for CRPC.
  5. Oversee comorbid conditions and describe their management in the context of CRPC treatment.
  6. Manage both the acute and chronic pain that is inherent in the care of CRPC patients.
  7. Communicate the pertinent end-of-life issues that surround CRPC patients and their families.
Course summary
Available credit: 
  • 7.75 AMA PRA Category 1 Credit™
  • 7.75 Non-Physician Participation
Course opens: 
08/05/2017
Course expires: 
10/29/2020
Event starts: 
10/29/2017 - 7:00am EDT
Event ends: 
10/29/2017 - 5:00pm EDT
Add to calendar: 
Rating: 
0

7:00 – 8:00 am            Registration & Continental Breakfast

8:00 – 8:15 am            Welcome & Introduction

                                    Adam S. Kibel, MD

8:15 – 8:30 am            Pre-Test

                                    Adam S. Kibel, MD

Session I: Guidelines and Treatment Strategies

8:30 – 9:15 am            Overview of AUA CRPC Guidelines for FDA Approved Agents in the Management of CRPC

                                    Adam S. Kibel, MD

9:15 – 10:00 am          Treatment Sequencing and Combinatorial Strategies in CRPC         

                                    Tanya B. Dorff, MD                           

10:00 – 10:05 am        Session I Post- Test

                                    Tanya B. Dorff, MD   

10:05 – 10:20 am        Break

Session II: Side Effect Management and Toxicities of Therapy

10:20 – 11:05 am        Comorbidities and Side Effect Profiles – Considerations for Various CRPC Therapeutic Strategies

                                    Evan Y. Yu, MD                                   

11:05 – 11:50 am        Future Directions in Systemic Therapy          

                                    Evan Y. Yu, MD

11:50 – 12:35 pm        Bone Health and Management of Toxicities of Therapy in the Context of CRPC Treatment

                                    Robert E. Reiter, MD

12:35 –12:40 pm         Session II Post- Test

                                    Robert E. Reiter, MD

12:40 – 1:50 pm          Lunch

                                    A Non-CME Lunch Symposium supported by Astellas Pharma US, Inc. and Pfizer Oncology

Session III: Practical Management of a CRPC Clinic

1:50 – 2:20 pm            Practical Guide to an Advanced Prostate Cancer Clinic

                                    Lawrence I. Karsh, MD 

2:20 – 2:50 pm            Panel Discussion

                                    All Faculty, Moderator: Lawrence I. Karsh, MD

Session IV: Quality and End-of Life Issues in CRPC

2:50 – 3:20 pm            Acute and Chronic Pain Management in CRPC

                                    Edouard J. Trabulsi, MD

3:20 – 3:50 pm            End-of-life Issues in CRPC Patients and Their Families                                  

                                    Tanya B. Dorff, MD

3:50 – 3:55 pm            Session IV Post-Test

                                    Tanya B. Dorff, MD

3:55 – 4:10 pm            Break

Session V: Revisiting the Index Patients with a New Perspective

4:10 – 4:50 pm            Case Study 1 & 2

                                    Round Table Case Discussions

                                    Questions and Review of Cases

                                    Lawrence I. Karsh, MD & Tanya B. Dorff, MD

4:50 – 5:30 pm            Case Study 3 & 4

                                    Round Table Case Discussions

                                    Questions and Review of Cases

                                    Edouard J. Trabulsi, MD & Robert E. Reiter, MD

5:30 pm                       Course Adjourn

 

Omni Los Angeles Hotel at California Plaza
Los Angeles, CA
United States

Name

Company

Role

Financial

Tanya B. Dorff, MD

Bayer

Meeting Participant or Lecturer, Scientific Study or Trial

Yes

Exelixis

Meeting Participant or Lecturer

Yes

Pfizer

Consultant or Advisor, Meeting Participant or Lecturer

Yes

 Lawrence I. Karsh,MD

Astellas

Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial

Yes

Dendreon

Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial

Yes

Bayer

Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial

Yes

Janssen

Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial

Yes

Medivation

Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial

Yes

Genomic Health

Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial

Yes

Myriad

Consultant or Advisor, Scientific Study or Trial

Yes

Swan Valley Medical

Consultant or Advisor, Investment Interest

Yes

imageAmgen

Scientific Study or Trial

Yes

Heat Biologics

Scientific Study or Trial

Yes

Bavaria Nordic Immunotherapy

Consultant or Advisor, Scientific Study or Trial

Yes

MDxHealth

Scientific Study or Trial

Yes

Lawrence Karsh

Health Publishing, Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial, Investment Interest

Yes

Spectrum Pharmaceuticals

Consultant or Advisor, Scientific Study or Trial

Yes

FKD

Scientific Study or Trial

Yes

Pfizer

Consultant or Advisor

Yes

Sanofi

Consultant or Advisor

Yes

Tolmar

Consultant or Advisor

Yes

Ferring

Consultant or Advisor

Yes

Abbvie

Consultant or Advisor

Yes

Argos

Consultant or Advisor, Scientific Study or Trial

Yes

Astra-Zeneca

Consultant or Advisor

Yes

Augmenix

Consultant or Advisor, Scientific Study or Trial

Yes

Precision Biopsy

Consultant or Advisor, Scientific Study or Trial

Yes

Takeda

Consultant or Advisor, Scientific Study or Trial

Yes

Tokai

Consultant or Advisor, Scientific Study or Trial

Yes

3D BIopsy

Consultant or Advisor, Scientific Study or Trial

Yes

GenomeDx BIosciences

Consultant or Advisor, Scientific Study or Trial

Yes

Precision Med

Scientific Study or Trial

Yes

Adam S. Kibel, MD

Sanofi-Aventis

Consultant or Advisor, Scientific Study or Trial

Yes

MTG

Consultant or Advisor

Yes

Profound

Consultant or Advisor

Yes

Dendreon

Consultant or Advisor

Yes

imageAlicia K. Morgans,  MD, MPH

AstraZeneca

Consultant or Advisor

Yes

 Robert E. Reiter, MD

ImaginAb Corporation

Investment Interest

Yes

Charles J. Ryan, MD

Johnson and Johnson

Consultant or Advisor

Yes

 

Scientific Study or Trial

Yes

Millennium

Consultant or Advisor

Yes

Janssen

Meeting Participant or Lecturer

Yes

Bayer

Consultant or Advisor

Yes

Ferring

Consultant or Advisor

Yes

Xcell Biosciences

Other : Equity

Yes

Astellas

Meeting Participant or Lecturer

Yes

AstraZeneca

Consultant or Advisor

Yes

Karyopharm

Scientific Study or Trial

Yes

 Kelly L. Stratton, MD

Ebix

Other : Contributor

Yes

Bayer Corporation

Consultant or Advisor

Yes

MDXHealth

Consultant or Advisor

Yes

Oakstone

Other : Professional Service

Yes

Edouard J. Trabulsi, MD

 

Consultant or Advisor

Yes

 Evan Y. Yu, MD

Agensys

Consultant or Advisor, Scientific Study or Trial

Yes

Genentech

Meeting Participant or Lecturer, Scientific Study or Trial

Yes

Bayer

Scientific Study or Trial

Yes

 

Consultant or Advisor

Yes

Merck

Scientific Study or Trial

Yes

Astellas

Consultant or Advisor, Scientific Study or Trial

Yes

Janssen

Consultant or Advisor

Yes

Merck

Consultant or Advisor

Yes

Voluntis

Consultant or Advisor

Yes

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Available Credit

  • 7.75 AMA PRA Category 1 Credit™
  • 7.75 Non-Physician Participation
Please login or register to take this course.